The article offers information about the increasing use of Neoadjuvant Chemoimmunotherapy in advanced ovarian cancer. It mentions that dual immune checkpoint inhibition with the anti–PD-L1 antibody durvalumab (Imfinzi) and the investigational anti– CTLA-4 antibody tremelimumab combined with platinum-based chemotherapy showed promising clinical activity in advanced ovarian cancer.